About
Technology
Issues
FAQ
Links
Official Page
Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.